Monoclonal and polyclonal antibodies relating to fragile X syndrome
US6242576A · kind A · utility
6Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 2, 1995 |
| Grant date | Jun 5, 2001 |
| Priority date | — |
| Expiry date | Jun 2, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The DNA sequence spanning the fragile X site on the X human chromosome has been obtained in purified and isolated form. As fragile X is associated with mental retardation, the availability of a DNA which spans this locus permits diagnosis and treatment of the related mental disorders. Polyclonal and monoclonal antibodies to an amino acid sequence encoded by SEQ ID NO:1, a DNA sequence from the Fragile X site, are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.